Isomorphic (Koebner) Phenomenon Induced by Insulin Analogue Injections in Psoriasis.

diabetes mellitus injection sites insulin therapy koebnerization psoriasis

Journal

JCEM case reports
ISSN: 2755-1520
Titre abrégé: JCEM Case Rep
Pays: England
ID NLM: 9918609886906676

Informations de publication

Date de publication:
Jan 2023
Historique:
received: 22 08 2020
medline: 1 11 2023
pubmed: 1 11 2023
entrez: 1 11 2023
Statut: epublish

Résumé

Koebner phenomenon is an uncommon skin-related complication of subcutaneous insulin injection in patients with diabetes mellitus. This reaction, also referred as isomorphic phenomenon, has previously been described in various conditions including vitiligo, lichen planus, and psoriasis. We report a 56-year-old woman insulin-treated patient with type 2 diabetes mellitus who developed new-onset, sharply well-demarcated erythematous scaly plaques at the insulin injection sites consistent with Koebner phenomenon. These lesions occurred after withdrawal of methotrexate initiated for the treatment of psoriasis. The lesions responded well to guselkumab, an interleukin-23 targeting agent but not ciclosporin. Of note, unlike previously reported cases, our patient developed isomorphic response under treatment with insulin analogues and during psoriasis flare-up. This case highlights the paramount role of thorough and cautious examination of injection and insertion sites in patients at risk undergoing subcutaneous continuous glucose monitoring or treated with continuous transdermal/subcutaneous insulin injections.

Identifiants

pubmed: 37908249
doi: 10.1210/jcemcr/luac016
pii: luac016
pmc: PMC10578368
doi:

Types de publication

Case Reports

Langues

eng

Pagination

luac016

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society.

Références

BMJ. 2020 May 28;369:m1590
pubmed: 32467098
Br J Dermatol. 2013 Oct;169(4):783-93
pubmed: 23772556
Actas Dermosifiliogr. 2010 Jul;101(6):563-5
pubmed: 20738983
Diabetes Care. 2022 Jan 1;45(Suppl 1):S46-S59
pubmed: 34964869
Am J Clin Dermatol. 2003;4(10):661-7
pubmed: 14507228
JAMA Dermatol. 2016 Aug 1;152(8):919
pubmed: 27532355
Am J Med. 2010 Jun;123(6):514-6
pubmed: 20569755
Eur J Dermatol. 2011 Sep-Oct;21(5):807-8
pubmed: 21737378
Dermatology. 2007;215(2):114-7
pubmed: 17684372

Auteurs

Saartje Thijs (S)

Department of Diabetes and Endocrinology, VITAZ Hospital, Sint-Niklaas, Belgium.

Eric Balti (E)

Department of Diabetes and Endocrinology, VITAZ Hospital, Sint-Niklaas, Belgium.

Corinne Degraeve (C)

Molenstraat 160 Private Dermatology Clinic, Kruibeke, Belgium.

Peter Coremans (P)

Department of Diabetes and Endocrinology, VITAZ Hospital, Sint-Niklaas, Belgium.

Classifications MeSH